MoonLake Immunotherapeutics
MLTX
$3.28
Change (1 day)
$64.98
Year High
$35.11
Year Low
Categories
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics (MLTX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.06 M | -447,471,471 | 13.05 M | 526.54 M | 514.17 M |
| 2022 | 217.13 K | -39,223,047 | 8.08 M | 76.84 M | 76.51 M |
| 2021 | 148.77 K | 6.96 M | 21.33 M | 9.68 M | 9.64 M |
| 2020 | -1,277,861 | 4.15 M | 116.63 M | 1.62 M |